5 Key Takeaways
-
1
Two complement inhibitors are approved for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
2
Both treatments slow GA progression and may extend functional vision for patients when administered monthly or bi-monthly.
-
3
Recent terminology for GA includes optical coherence tomography (OCT) criteria, emphasizing the need for advanced imaging for accurate diagnosis.
-
4
GA can be confused with other conditions affecting the outer retina, making accurate diagnosis critical to ensure appropriate treatment.
-
5
Current GA treatments are only approved for AMD, and their efficacy in non-AMD conditions remains unverified.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.